Disclosed herein is a chemo-proteomic probe for labelling and monitoring a live microbe interacting with a host cell and for qualitative and quantitative analyses of those proteins involved during a microbe infects the host cell. This probe comprises a functional group for conjugating to a surface protein of a live microbe under a physiological condition; a photo-reactive group for covalent cross-linking to an interacting cell protein of a host; and a tag for isolating the cross-linked complex of the surface protein of said live microbe and the interacting protein of a host cell for qualitative and quantitative proteomics analyses. The probe may further comprise a visualization tag. This technology takes advantage of the high throughput feature of mass spectrometry analysis and combines it with a uniquely designed chemistry to achieve high efficient isolation and analysis of host cell proteins interacting with a pathogen at different stages of an infection.

Disclosed is an antibody, functional fragment, and derivative thereof, which binds specifically to the OAcGD2 ganglioside, the antibody including i) a humanized light chain variable region (VL) polypeptide having the amino acid sequence SEQ id n°112; and ii) a humanized heavy chain variable region (VH) having the amino acid sequence SEQ id n°76; and its use in diagnostics and therapy.

The invention relates to the new application of medicine, in particular to the laboratory cancer diagnostics. It describes a set of reagents for detecting the marker for epithelial carcinomas CA-62 in patients' blood serum for early detection of cancer, detecting cancer recurrences and monitoring cancer treatment of human epithelial tumors using immunochemical analysis. The main difference between the CA-62 cancer marker and other well-known markers comprises of the fact that the maximum peak of its expression falls on the very beginning of cancer development. This makes it possible to detect the early stages of tumor growth with high sensitivity and specificity when the cure rate is at maximum. The dynamics of the CA-62 marker level also show high efficacy in detecting tumor recurrences and monitoring the treatment of patients with advanced cancer. The set of reagents includes a microplate with immobilized antibodies to a CA-62 cancer antigen, CA-62-Acridinium conjugate, CA-62 standard calibrators in the measurement range from 10 to 30000 U/ml, CA-62 positive control, working buffer solution (pH 2.0-8.0) containing Tween-80.

The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.

The present invention provides a method for labeling or detecting a protein with certain glycosyl groups. The methods are particularly useful for detecting cancer cells comprising the detected glycosyl groups. The present invention further provides labeling agents and detection agents, labeled proteins and mixtures, and kits and arrays thereof.

The invention relates generally to polypeptides comprising a lectin domain, multimeric proteins comprising the polypeptides, and use of the polypeptides or multimeric proteins in the detection of a carbohydrate (e.g., a sialic acid containing carbohydrate or Siglec ligand) or the treatment of a Siglec-mediated disorder.

Disclosed are biomarkers for Barrett's esophagus and esophageal adenocarcinoma, and uses thereof, such as in methods for detecting the presence, and monitoring progression, of Barrett's esophagus and esophageal adenocarcinoma. Also disclosed are methods for treating and methods of monitoring the treatment of Barrett's esophagus and esophageal adenocarcinoma, as well as kits and compositions for use in such methods.

Disclosed is an antibody, functional fragment, and derivative thereof, which binds specifically to the OAcGD2 ganglioside, the antibody including i) a humanized light chain variable region (VL) polypeptide having the amino acid sequence SEQ id no 112; and ii) a humanized heavy chain variable region (VH) having the amino acid sequence SEQ id no 76; and its use in diagnostics and therapy.

The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.

Lung cancer can be detected by measuring sites in pancreatic ribonuclease 1 (also abbreviated as “RNase 1”), wherein each of the sites is a site capable of being modified with an N-linked sugar chain. Lung cancer is detected by measuring items A and B as mentioned below and then comparing the ratio of the value of A to the value of B: A=the amount of sites in pancreatic ribonuclease 1, wherein the sites are sites each capable of being modified with an N-linked sugar chain and each having an N-linked sugar chain bound thereto or each having an N-linked sugar chain unbound thereto; and B=the amount of sites in pancreatic ribonuclease 1, wherein the sites are sites each capable of being modified with an N-linked sugar chain.